We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Aventis Loses Second Lovenox Patent Reissuance Bid

Law360 (July 27, 2004, 12:00 AM EDT) -- French drug maker Aventis SA has vowed to continue fighting for a reissuance of a patent for its best-selling anti-blood clotting drug Lovenox, even though its application was rejected twice by the U.S. Patent & Trademark Office.

Aventis said Tuesday it received a second rejection from the USPTO on its application for reissuance of U.S. patent no. 5,389,618 ('618 patent), which covers Lovenox.

Aventis filed an application with the USPTO to try to reissue the ‘618 patent in May 2003. Reissuance applications are typically used to...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.